SCHEMBL2838593

SCHEMBL2838593

[CH2]CC(C)OC(=O)c1ccccc1C

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
KDM4E B2RXH2 1/20 0.56
ADRB2 P07550 2/20 0.47
ADRB1 P08588 2/20 0.47
ADRB3 P13945 2/20 0.47
UTS2R Q9UKP6 1/20 0.45
ALDH1A1 P00352 3/20 0.44
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14690195 0.86 SMN1; SMN2 (0.59) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL2408720 0.86 SMN1; SMN2 (0.59) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL13328208 0.85 SMN1; SMN2 (0.58) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL15110945 0.85 SMN1; SMN2 (0.58) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL17797889 0.82 ALDH1A1 (0.62) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL8995973 0.81 SMN1; SMN2 (0.54) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL1786549 0.80 SMN1; SMN2 (0.52) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL277670 0.80 NPC1 (0.56) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL27533098 0.80 SMN1; SMN2 (0.53) SMN1; SMN2KDM4EADRB2ADRB1ADRB3
SCHEMBL27681565 0.79 ADRB2 (0.51) SMN1; SMN2KDM4EADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016182898-A1 METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF XENOPORT, INC. (US) 2016-11-17 WO disclosed
EP-3027767-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XenoPort, Inc. (US) 2016-06-08 EP disclosed
EP-2887934-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XenoPort, Inc. (US) 2015-07-01 EP disclosed
WO-2015017762-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XENOPORT, INC. (US) 2015-02-05 WO disclosed
WO-2014031901-A1 METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF XENOPORT, INC. (US) 2014-02-27 WO disclosed
WO-2014031844-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XENOPORT, INC. (US) 2014-02-27 WO disclosed
WO-2010022177-A2 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2010-02-25 WO disclosed